SITC: Cellectis' off-the-shelf CAR-T for pancreatic cancer and mesothelioma shows activity in mice

Cellectis has suffered some setbacks in its efforts to develop CAR-T treatments for cancer that would be universal rather than made from individual patients’ immune cells, as are currently available CAR-Ts. But the company is pressing ahead with several attempts at off-the-shelf CAR-Ts—and, now, it has preliminary data to back up one such effort that’s aimed at solid tumors.